Herpes zoster : treatment, management, and prevention with the recombinant DNA vaccine
Herpes zoster (HZ) is a reactivation of dormant varicella-zoster virus that most often erupts as painful vesicles in a unilateral dermatomal distribution. A sequela of HZ is postherpetic neuralgia (PHN), which is debilitating and may be persistent. Therefore, vaccination for the prevention of HZ and its sequelae is recommended for adults aged 50 years and older as well as immunocompromised adults. In 2017, the US Food and Drug Administration approved a recombinant DNA vaccine (Shingrix) that is safe to use in immunocompromised individuals and an improvement on the live-attenuated vaccine approved in 2006. This report discusses HZ, PHN, treatment of HZ and PHN, and prevention with vaccines.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
General dentistry - 72(2023), 1 vom: 20. Jan., Seite 54-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Emily [VerfasserIn] |
|---|
| Themen: |
Attenuated vaccines |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM366083112 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366083112 | ||
| 003 | DE-627 | ||
| 005 | 20231227140039.0 | ||
| 007 | tu | ||
| 008 | 231227s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM366083112 | ||
| 035 | |a (NLM)38117642 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Emily |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Herpes zoster |b treatment, management, and prevention with the recombinant DNA vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Herpes zoster (HZ) is a reactivation of dormant varicella-zoster virus that most often erupts as painful vesicles in a unilateral dermatomal distribution. A sequela of HZ is postherpetic neuralgia (PHN), which is debilitating and may be persistent. Therefore, vaccination for the prevention of HZ and its sequelae is recommended for adults aged 50 years and older as well as immunocompromised adults. In 2017, the US Food and Drug Administration approved a recombinant DNA vaccine (Shingrix) that is safe to use in immunocompromised individuals and an improvement on the live-attenuated vaccine approved in 2006. This report discusses HZ, PHN, treatment of HZ and PHN, and prevention with vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a attenuated vaccines | |
| 650 | 4 | |a herpes zoster | |
| 650 | 4 | |a postherpetic neuralgia | |
| 650 | 4 | |a recombinant DNA vaccines | |
| 650 | 4 | |a varicella-zoster virus | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 650 | 7 | |a Herpes Zoster Vaccine |2 NLM | |
| 700 | 1 | |a Closmann, James J |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Richard C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t General dentistry |d 1987 |g 72(2023), 1 vom: 20. Jan., Seite 54-57 |w (DE-627)NLM000383325 |x 0363-6771 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:54-57 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 1 |b 20 |c 01 |h 54-57 | ||